Developmental Cancer Therapeutics

发育性癌症治疗

• 批准号: 10059207
• 负责人: DAVID A. HORNE
• 金额: $ 6.18万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10059207
• 关键词: Achievement; Adenosine; Area; Basic Science; Biological; Biological Markers; Biological Products; Biology; Cancer Center Support Grant; Cell Proliferation; Cell Therapy; Chemicals; City of Hope Comprehensive Cancer Center; Clinic; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Comprehensive Cancer Center; Contracts; Cyclic GMP; Development; Doctor of Philosophy; Drug Delivery Systems; Enzymes; Faculty; Formulation; Fostering; Funding; Genomic approach; Glioma; Goals; Gold; Grant; Histones; Immunotherapy; Infrastructure; Investigation; Lead; Leadership; Libraries; Ligands; Malignant Neoplasms; Mediating; Mission; Molecular; Molecular Target; Natural Products; Neoplasm Metastasis; Oncology; Oncolytic viruses; Outcome; Pathway interactions; Patients; Peer Review; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Prodrugs; Publications; RNA Synthesis Inhibitors; Research; Research Personnel; Ribonucleotide Reductase Inhibitor; Scientist; Solid Neoplasm; Specificity; Specimen; Speed; System; Technology; Therapeutic; Tissues; Toxic effect; Toxicology; Transferase; Translating; Translations; Tumor Subtype; Work; angiogenesis; baicalein; base; bench to bedside; cancer stem cell; cancer therapy; clinical efficacy; clinical investigation; design; drug development; drug discovery; early phase clinical trial; falls; first-in-human; high throughput screening; improved; industry partner; inhibitor/antagonist; innovation; inter-institutional; mTOR Inhibitor; member; molecular subtypes; molecular targeted therapies; nanoparticle; neoplastic cell; nerve stem cell; novel; novel therapeutic intervention; novel therapeutics; precision medicine; preclinical study; predicting response; programs; recruit; screening; side effect; small molecule; stem cell self renewal; stem cells; targeted agent; targeted cancer therapy; targeted delivery; targeted treatment; therapy development; translational research program; tumor; virtual

Developmental Cancer Therapeutics Program ABSTRACT The Developmental Cancer Therapeutics (DCT) Program has evolved considerably since 2012 with an increased focus on both solid tumor oncology and the translational aspects of advancing basic science into early-phase clinical trials in rapid fashion. Under the leadership of David Horne, PhD and Edward Newman, PhD, the central theme and overarching goal of DCT are the in-house development of novel, molecularly targeted therapies and drug delivery systems for intractable cancers. Although DCT has continued the Program's long- standing strength in evaluating cancer therapeutics developed through industry partnerships, the emphasis of the DCT Program is to advance important basic discoveries made at the City of Hope Cancer Comprehensive Center (COHCCC). To this end, DCT has established clear scientific goals that fall under three central themes: 1) Support target-directed drug development by identifying and validating new molecular cancer targets/pathways and developing corresponding pharmacological agents; 2) Develop novel drug delivery platforms to improve specificity and efficacy of clinical outcomes; and 3) Translate basic discovery and preclinical studies into early-phase clinical trials. The DCT program extends across eight departments and encompasses a total of 29 Members, of which 12 are basic researchers and 17 are clinicians/clinician scientists. Through the Program, close intra- and inter-programmatic collaborations are fostered among basic scientists and clinical investigators, which in turn has yielded an increase in the number of COH-initiated agents currently under clinical investigation. During the previous grant period, significant infrastructure has been established for the creation of a strong translational research program with greater focus on solid tumor oncology, resulting in a continuous flow of new therapeutic approaches poised for early-phase clinical trials. The emphasis is on speed and precision medicine. With only GLP toxicity studies and some formulation work contracted outside, the DCT Program can rapidly translate discoveries to the clinic. This Program has been further enhanced by the strategic recruitment of key faculty (Chen, Fakih, Fong, Gold, and Salgia), implementation of a drug discovery pipeline, and cGMP manufacturing capability for small molecule drugs, such as COH29, through COH’s in-house Chemical cGMP Synthesis Facility. During the next funding period, we anticipate robust translation of our new therapeutic approaches from the discovery phase to first-in-human clinical trials and continued close collaboration with other regional and national Comprehensive Cancer Centers. Membership: 29 Program Members representing 8 basic and clinical departments Publications: 503 total. 20.1% intra-programmatic; 36.4% inter-programmatic; 41.2% inter-institutional Funding: $4,751,305 peer-reviewed; $1,794,235 of which is NCI funding

发展癌症治疗计划 摘要 发展性癌症治疗（DCT）计划自2012年以来已经有了很大的发展， 更多地关注实体瘤肿瘤学和推进基础科学转化为 快速进行早期临床试验。在大卫霍恩博士和爱德华纽曼博士的领导下， DCT的中心主题和首要目标是在内部开发新颖的、分子靶向的 用于难治性癌症的治疗和药物输送系统。虽然华为一直坚持长期以来的... 通过行业伙伴关系开发的癌症治疗评估的长期优势， DCT计划是为了促进在希望之城癌症综合研究所取得的重要基础发现 中心（COHCCC）。为此，DCT制定了明确的科学目标，这些目标属于三个中心主题： 1)通过识别和验证新的分子癌症来支持靶向药物开发 靶点/途径和开发相应的药理学试剂; 2）开发新的药物递送 平台，以提高临床结果的特异性和有效性;和3）翻译基础发现和临床前 进入早期临床试验阶段。DCT计划跨越八个部门，包括 共有29名成员，其中12名是基础研究人员，17名是临床医生/临床科学家。通过 计划，密切的内部和跨计划的合作，促进基础科学家和临床 研究者，这反过来又增加了目前正在临床研究的COH启动的药物数量 调查在上一个赠款期间，为建立 一个强大的转化研究计划，更加关注实体瘤肿瘤学，从而实现持续的 为早期临床试验准备的新治疗方法的流动。重点是速度和精度 药由于只有GLP毒性研究和一些外部承包的制剂工作，DCT计划可以 快速将发现转化为临床。该计划通过战略招聘得到进一步加强 关键教师（陈，Fakih，方，黄金和Salgia），药物发现管道的实施，和cGMP 通过COH的内部化学cGMP生产小分子药物，如COH 29 合成设施。在下一个资助期内，我们预计我们的新治疗药物将得到有力的翻译。 从发现阶段到首次人体临床试验的方法，并继续与其他 区域和国家综合癌症中心。 成员：29名计划成员，代表8个基础和临床部门 出版物：共计503份。方案内20.1%;方案间36.4%;机构间41.2% 资金：4，751，305美元同行评审;其中1，794，235美元为NCI资金